title: Imatinib discontinuation for hypereosinophilic syndrome harboring the FIP1L1-PDGFRA transcript.
authors.affiliation: a School of Medicine in Katowice, Department of Hematology and Bone Marrow Transplantation , Silesian Medical University , Katowice , Poland .
authors.forename: Grzegorz
authors.initials: G
authors.lastname: Helbig
authors.affiliation: a School of Medicine in Katowice, Department of Hematology and Bone Marrow Transplantation , Silesian Medical University , Katowice , Poland .
authors.forename: Anna
authors.initials: A
authors.lastname: Soja
authors.affiliation: b Department of Hematology , Regional Hospital , Zielona Góra , Polan , and.
authors.forename: Alina
authors.initials: A
authors.lastname: Świderska
authors.affiliation: c Department of Hemato-Oncology and Bone Marrow Transplantation , Medical University , Lublin , Poland.
authors.forename: Marek
authors.initials: M
authors.lastname: Hus
authors.affiliation: a School of Medicine in Katowice, Department of Hematology and Bone Marrow Transplantation , Silesian Medical University , Katowice , Poland .
authors.forename: Sławomira
authors.initials: S
authors.lastname: Kyrcz-Krzemień
mesh_terms: D006801:Humans; D017681:Hypereosinophilic Syndrome / Q000188:drug therapy* / Q000235:genetics* / Q000401:mortality; D000068877:Imatinib Mesylate / Q000008:administration & dosage / Q000627:therapeutic use*; D015514:Oncogene Proteins, Fusion / Q000235:genetics*; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D020796:Receptor, Platelet-Derived Growth Factor alpha / Q000235:genetics*; D012008:Recurrence; D016896:Treatment Outcome; D039221:mRNA Cleavage and Polyadenylation Factors / Q000235:genetics*
chemical_list: D015514:Oncogene Proteins, Fusion; D047428:Protein Kinase Inhibitors; D039221:mRNA Cleavage and Polyadenylation Factors; D000068877:Imatinib Mesylate; C479819:FIP1L1-PDGFRA fusion protein, human; D020796:Receptor, Platelet-Derived Growth Factor alpha